Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease

Metabolism and Target Organ Damage, Год журнала: 2024, Номер 4(3)

Опубликована: Июль 29, 2024

Steatotic liver disease (SLD), including metabolic dysfunction-associated steatotic (MASLD) and alcohol-associated (ALD), is the primary cause of illness mortality. In particular, MASLD affects more than 30% global population, while ALD accounts for 5.1% all diseases injuries worldwide. The SLD spectrum includes a variety clinical conditions, from mild fatty inflammation to different stages fibrosis. Additionally, both conditions (MASLD ALD) can be complicated by hepatocellular carcinoma (HCC), around one-third patients also develop at least one alcohol‐associated hepatitis (AH) episode. Both these are associated with multiple extrahepatic complications, such as cardiovascular disease, chronic kidney malignancies. MASLD, rapid rise in obesity type 2 diabetes mellitus (T2DM) prevalence due Westernized lifestyles has led an increase MASLD. Thus, prevention control cardiometabolic risk factors (CMRFs) cornerstone its treatment. Hypertension atherogenic dyslipidemia important CMRFs Susceptible individuals adversely affected even small amount alcohol consumption (though there no agreed definition amount), increasing severe outcomes faster progression disease. This review explores that play role development SLD, especially focusing on management levels use prevent progression.

Язык: Английский

Metabolic Dysfunction-Associated Steatotic Liver Disease - a New Indication for Sodium-Glucose Co-Transporter-2 Inhibitors

Advances in Medical Sciences, Год журнала: 2024, Номер 69(2), С. 407 - 415

Опубликована: Сен. 1, 2024

Язык: Английский